Sanofi et GSK débutent une étude internationale de phase III pour évaluer l efficacité de leur candidat-vaccin contre la COVID-19 - La Bourse et la Vie TV L information éco à valeur ajoutée labourseetlavie.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labourseetlavie.com Daily Mail and Mail on Sunday newspapers.
Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
FX-06 is a synthetic peptide with a broad spectrum of potential applications associated with endothelial barrier integrity, blood vessel permeability and inflammation
Potential applications include COVID-19, pandemic, chemical, biological, radiological and nuclear threats
News provided by
Share this article
Share this article
LEXINGTON, Mass., March 3, 2021 /PRNewswire/ Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications. The partnership will focus on exploring potential collaborations with the U.S. Government to develop FX-06 as a medical countermeasure against high priority threats for which there are s